ZenBio will offer low passage cryopreserved and cultured forms of 3T3-L1 cells with optimized media formulations to enhance growth and survival rates in culture. In addition, ZenBio will offer contract research services tailored to the 3T3-L1 in vitro system. Capabilities will include assay development, compound screening, conditioned media delivery, gene expression profiling and further 3T3-L1 characterization. ZenBio will also offer optimized metabolic research kits to measure various outputs from 3T3-L1 assays, including insulin-stimulated glucose uptake, lipolysis and triglyceride accumulation.

In order to make it easier for its HTS/HCA partners to incorporate 3T3-L1 cells into their screening programs, ZenBio will also offer large-scale, pre-plated cell cultures for use in automated screening projects on a custom basis. A variety of SBS-approved plate formats and flask cultures will be available.

The 3T3-L1 cell line is an excellent addition to our portfolio of human primary cell products and assays, says Peter Pieraccini, President of ZenBio. Metabolic disease research has the potential to provide solutions to widespread, serious health problems, and we are committed to continuing to lead in offering cell-based solutions for researchers.

SOURCE ZenBio, Inc.